What type of study is this?

October 11, 2025BJC ReportsOpen Access

Too much or too little? The trajectory of systemic anti-cancer treatment throughout the last year of life of lung cancer patients in Norway

View Full Paper

Ask AI

Bookmark

Authors

SSSteinar SolbergOslo University Hospital KSKathinka Schmidt SlørdahlOslo University Hospital MAMarianne AanerudHaukeland University Hospital

Discussion

Member takes

Implication

Observational analysis reports low rates of systemic anti-cancer treatment in lung cancer patients, highlighting treatment dynamics and predictors of use.

Key Points

Only 8.9% of patients received systemic anti-cancer treatment at 30 days before death, indicating low end-of-life utilization.
Chemotherapy and immunotherapy use reduced significantly as patients approached death, impacting treatment strategies.
Younger age, male sex, and good performance status were key predictors for receiving treatment 30 days before death.
The findings suggest that older patients and those with poor performance status are less likely to receive systemic anti-cancer treatments.

Cite This Study

Solberg et al. (2025) studied this question.

synapsesocial.com/papers/68e9b1b5ba7d64b6fc131f5b https://doi.org/10.1038/s44276-025-00183-w

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis reports low rates of systemic anti-cancer treatment in lung cancer patients, highlighting treatment dynamics and predictors of use.

Too much or too little? The trajectory of systemic anti-cancer treatment throughout the last year of life of lung cancer patients in Norway

Discussion

Member takes

Implication

Key Points

Cite This Study

Too much or too little? The trajectory of systemic anti-cancer treatment throughout the last year of life of lung cancer patients in Norway

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider